{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:56Z","timestamp":1707524216232},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,26]]},"DOI":"10.7759\/cureus.15249","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T11:42:26Z","timestamp":1622029346000},"source":"Crossref","is-referenced-by-count":0,"title":["Maculopapular Exanthema After the Second Dose of Evolocumab"],"prefix":"10.7759","author":[{"given":"Victoria","family":"Ghernautan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issac","family":"Sachmechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"15","author":"Roujeau JC","year":"2005","unstructured":"Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005, 15:123-9. 10.1016\/j.tox.2004.12.022","journal-title":"Toxicology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung WH","year":"2016","unstructured":"Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016, 43:758-66. 10.1111\/1346-8138.13430","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2010.04.007","article-title":"Danger signs in drug hypersensitivity","volume":"94","author":"Scherer K","year":"2010","unstructured":"Scherer K, Bircher AJ. Danger signs in drug hypersensitivity. Med Clin North Am. 2010, 94:681-9. 10.1016\/j.mcna.2010.04.007","journal-title":"Med Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01960.x","article-title":"Drug allergy and hypersensitivity: still a hot topic","volume":"64","author":"Bousquet PJ","year":"2009","unstructured":"Bousquet PJ, Demoly P, Romano A. Drug allergy and hypersensitivity: still a hot topic. Allergy. 2009, 64:179-82. 10.1111\/j.1398-9995.2008.01960.x","journal-title":"Allergy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy","volume":"37","author":"Patel SV","year":"2017","unstructured":"Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017, 37:397-412. 10.1016\/j.iac.2017.01.012","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.14772","article-title":"Repatha (evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Repatha (evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia. Am Health Drug Benefits. 2016, 9:136-9. 10.1001\/jama.2015.14772","journal-title":"Am Health Drug Benefits"},{"key":"ref7","article-title":"Evolocumab (Repatha) for the treatment of hyperlipidemia","volume":"94","author":"Erlich DR","year":"2016","unstructured":"Erlich DR. Evolocumab (Repatha) for the treatment of hyperlipidemia. Am Fam Physician. 2016, 94:843-6.","journal-title":"Am Fam Physician"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren MJ","year":"2019","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, et al.. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019, 74:2132-46. 10.1016\/j.jacc.2019.08.1024","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen SE","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al.. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016, 315:1580-90. 10.1001\/jama.2016.3608","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2019_86-309","article-title":"Atopic dermatitis-like rash during evolocumab treatment of familial hypercholesterolemia","volume":"86","author":"Kanda N","year":"2019","unstructured":"Kanda N, Okajima F. Atopic dermatitis-like rash during evolocumab treatment of familial hypercholesterolemia. J Nippon Med Sch. 2019, 86:187-90. 10.1272\/jnms.JNMS.2019_86-309","journal-title":"J Nippon Med Sch"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK9 inhibitors: a real-world experience","volume":"105","author":"G\u00fcrg\u00f6ze MT","year":"2019","unstructured":"G\u00fcrg\u00f6ze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther. 2019, 105:496-504. 10.1002\/cpt.1193","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.10.003","article-title":"Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open-label DE LAVAL study","volume":"13","author":"Baum SJ","year":"2019","unstructured":"Baum SJ, Sampietro T, Datta D, et al.. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open-label DE LAVAL study. J Clin Lipidol. 2019, 13:901-909.e3. 10.1016\/j.jacl.2019.10.003","journal-title":"J Clin Lipidol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60054-maculopapular-exanthema-after-the-second-dose-of-evolocumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:34Z","timestamp":1707506974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60054-maculopapular-exanthema-after-the-second-dose-of-evolocumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.15249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}